Brokers Set Expectations for OptiNose, Inc.’s FY2023 Earnings (NASDAQ:OPTN)
OptiNose, Inc. (NASDAQ:OPTN – Get Rating) – Stock analysts at Cantor Fitzgerald issued their FY2023 EPS estimates for shares of OptiNose in a report released on Monday, June 6th. Cantor Fitzgerald analyst B. Folkes anticipates that the company will post earnings of ($0.33) per share for the year.
Separately, Zacks Investment Research raised OptiNose from a “sell” rating to a “hold” rating in a research note on Friday, May 6th.
OPTN opened at $1.88 on Wednesday. The business has a 50 day moving average price of $2.22 and a two-hundred day moving average price of $2.17. The company has a market cap of $155.44 million, a PE ratio of -1.45 and a beta of 0.48. OptiNose has a 52 week low of $1.46 and a 52 week high of $3.85. OptiNose (NASDAQ:OPTN – Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.04). During the same quarter in the previous year, the firm posted ($0.49) earnings per share.
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
In related news, CEO Peter K. Miller sold 25,974 shares of OptiNose stock in a transaction on Wednesday, March 16th. The stock was sold at an average price of $2.11, for a total value of $54,805.14. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders sold 38,810 shares of company stock worth $81,889 in the last quarter. 6.00% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in the business. Rice Hall James & Associates LLC raised its position in OptiNose by 4.2% in the first quarter. Rice Hall James & Associates LLC now owns 881,665 shares of the company’s stock valued at $2,178,000 after purchasing an additional 35,498 shares during the period. Jane Street Group LLC purchased a new position in OptiNose in the first quarter valued at about $126,000. Goldman Sachs Group Inc. raised its position in OptiNose by 65.4% in the first quarter. Goldman Sachs Group Inc. now owns 91,492 shares of the company’s stock valued at $226,000 after purchasing an additional 36,174 shares during the period. State Street Corp raised its position in OptiNose by 87.8% in the first quarter. State Street Corp now owns 176,553 shares of the company’s stock valued at $436,000 after purchasing an additional 82,558 shares during the period. Finally, Prelude Capital Management LLC raised its position in OptiNose by 73.6% in the first quarter. Prelude Capital Management LLC now owns 125,000 shares of the company’s stock valued at $309,000 after purchasing an additional 53,000 shares during the period. 72.81% of the stock is currently owned by institutional investors.
About OptiNose (Get Rating)
OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Should you invest $1,000 in OptiNose right now?
Before you consider OptiNose, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and OptiNose wasn’t on the list.
While OptiNose currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
